AU2001255495A1 - Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rnain patients having chronic hepatitis c infection - Google Patents

Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rnain patients having chronic hepatitis c infection

Info

Publication number
AU2001255495A1
AU2001255495A1 AU2001255495A AU5549501A AU2001255495A1 AU 2001255495 A1 AU2001255495 A1 AU 2001255495A1 AU 2001255495 A AU2001255495 A AU 2001255495A AU 5549501 A AU5549501 A AU 5549501A AU 2001255495 A1 AU2001255495 A1 AU 2001255495A1
Authority
AU
Australia
Prior art keywords
rnain
ribavirin
infection
patients
combination therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001255495A
Inventor
Frank Bennett
Ashit K. Ganguly
Viyyoor M. Girijavallabhan
Raymond G. Lovey
Jinping Mccormick
Anil K. Saksena
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AU2001255495A1 publication Critical patent/AU2001255495A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
AU2001255495A 2000-04-20 2001-04-18 Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rnain patients having chronic hepatitis c infection Abandoned AU2001255495A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19880100P 2000-04-20 2000-04-20
US60198801 2000-04-20
PCT/US2001/012760 WO2001081359A1 (en) 2000-04-20 2001-04-18 Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection

Publications (1)

Publication Number Publication Date
AU2001255495A1 true AU2001255495A1 (en) 2001-11-07

Family

ID=22734903

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001255495A Abandoned AU2001255495A1 (en) 2000-04-20 2001-04-18 Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rnain patients having chronic hepatitis c infection

Country Status (5)

Country Link
US (2) US6924270B2 (en)
EP (1) EP1282632A1 (en)
AR (1) AR031572A1 (en)
AU (1) AU2001255495A1 (en)
WO (1) WO2001081359A1 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001255495A1 (en) 2000-04-20 2001-11-07 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rnain patients having chronic hepatitis c infection
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US6812219B2 (en) 2000-05-26 2004-11-02 Idenix Pharmaceuticals, Inc. Methods and compositions for treating flaviviruses and pestiviruses
US20060024270A1 (en) * 2000-08-23 2006-02-02 The New York Hospital Medical Center Of Queens Compositions and methods for preventing or treating encephalitis with interferon
CN1516599A (en) * 2000-10-18 2004-07-28 ���鹫˾ Method for joint treatment of chronic hepatitis C infection using ribavirin-polyvinyl glycol interferon alpha
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
KR20050048544A (en) 2002-06-28 2005-05-24 이데닉스 (케이만) 리미티드 Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections
MXPA04012802A (en) * 2002-06-28 2005-04-19 Idenix Cayman Ltd 2aCOE-C-METHYL-3aCOE-O-L-VALINE ESTER RIBOFURANOSYL CYTIDINE FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS.
CN101172993A (en) * 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US8476254B2 (en) 2002-07-02 2013-07-02 Corcept Therapeutics, Inc. Methods for treating psychosis associated with interferson-α therapy
RU2005118421A (en) * 2002-11-15 2006-01-20 Айденикс (Кайман) Лимитед (Ky) 2'-BRANCHED NUCLEOSIDES AND MUTATION FLAVIVIRIDAE
RU2005121904A (en) * 2002-12-12 2006-01-20 Айденикс (Кайман) Лимитед (Ky) METHOD FOR PRODUCING 2`-BRANCHED NUCLEOSIDES
US20040181051A1 (en) * 2002-12-23 2004-09-16 Richard Storer Process for the production of 3'-nucleoside prodrugs
ES2726998T3 (en) 2003-05-30 2019-10-11 Gilead Pharmasset Llc Modified fluorinated nucleoside analogs
EP1668031B1 (en) 2003-08-07 2008-03-12 ZymoGenetics, Inc. Homogeneous preparations of il-29
ZA200601181B (en) * 2003-08-13 2007-04-25 Smith Howard J & Ass Pty Ltd Method of treating viral infections
CA2537849A1 (en) * 2003-09-11 2005-03-17 F. Hoffmann-La Roche Ag Process for preparing antiviral nucleoside derivatives
US20050244423A1 (en) * 2004-04-02 2005-11-03 Klucher Kevin M Methods for treating viral infection using IL-28 and IL-29 cysteine mutants
BRPI0512360A (en) * 2004-06-23 2008-03-11 Idenix Cayman Ltd 5-aza-7-deazapurine derivatives for the treatment of flaviviridae
EP3109244B1 (en) 2004-09-14 2019-03-06 Gilead Pharmasset LLC Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
CN101048172A (en) * 2004-10-29 2007-10-03 英特塞尔股份公司 Hcv vaccines for chronic hcv patients
JP5409008B2 (en) 2005-11-11 2014-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド Hepatitis C virus variant
US7705138B2 (en) * 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
ES2422290T3 (en) * 2005-12-23 2013-09-10 Idenix Pharmaceuticals Inc Procedure for preparing a synthetic intermediate for the preparation of branched nucleosides
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
NZ593648A (en) 2008-12-23 2013-09-27 Gilead Pharmasset Llc Nucleoside phosphoramidates
TW201031675A (en) 2008-12-23 2010-09-01 Pharmasset Inc Synthesis of purine nucleosides
CN102753563A (en) 2008-12-23 2012-10-24 吉利德制药有限责任公司 Nucleoside analogs
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (en) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
CN102858790A (en) 2010-03-31 2013-01-02 吉利德制药有限责任公司 Nucleoside Phosphoramidates
AU2011268498A1 (en) 2010-06-24 2013-01-31 Genoscience Pharma Sas Treatment of hepatitis C virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
JP2013542206A (en) 2010-10-05 2013-11-21 ノバルティス アーゲー New treatment of hepatitis C virus infection
AU2011336632B2 (en) 2010-11-30 2015-09-03 Gilead Pharmasset Llc Compounds
EP2646038A1 (en) * 2010-11-30 2013-10-09 Novartis AG New treatments of hepatitis c virus infection
CN103476409A (en) 2011-03-31 2013-12-25 诺华股份有限公司 Alisporivir to treat hepatitis C virus infection
CN103648516A (en) 2011-04-13 2014-03-19 诺华股份有限公司 Treatment of hepatitis c virus infection with alisporivir
WO2012176149A1 (en) 2011-06-23 2012-12-27 Panmed Ltd. Treatment of hepatitis c virus
EP2709613B2 (en) 2011-09-16 2020-08-12 Gilead Pharmasset LLC Methods for treating hcv
AU2012314517A1 (en) * 2011-09-27 2014-04-17 Novartis Ag Alisporivr for treatment of Hepatis C virus infection
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
WO2014120981A1 (en) 2013-01-31 2014-08-07 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
WO2014122537A2 (en) 2013-02-05 2014-08-14 Genoscience Sa Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin
NZ716840A (en) 2013-08-27 2017-06-30 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
CN111320662B (en) * 2020-02-17 2022-11-25 南京医科大学 N-benzyl substituted diamidinonazine derivative and pharmaceutical application thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US3984396A (en) * 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
GB1482736A (en) 1974-03-18 1977-08-10 Icn Pharmaceuticals 1-(beta-d-ribofuranosyl)-1,2,4-triazole acid derivatives
US4544741A (en) 1982-03-29 1985-10-01 Robins Roland K Azole dinucleotide compounds and methods for their production
US5674911A (en) 1987-02-20 1997-10-07 Cytrx Corporation Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use
US4925930A (en) 1988-11-02 1990-05-15 Nucleic Acid Research Institute Synthesis and anti-leukemic activity of alkyl-1-(β-D-ribofuranosyl)[1,2,4]triazole-3-carboximidates
EP0625991B1 (en) * 1992-02-10 1999-04-28 Interferon Sciences, Inc. Improved alpha interferon composition and method for its production from human peripheral blood leukocytes
GB9307043D0 (en) * 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5981507A (en) 1995-12-14 1999-11-09 Advanced Magnetics, Inc. Polymeric carriers linked to nucleotide analogues via a phosphoramide bond
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
WO1998021223A1 (en) 1996-11-12 1998-05-22 Medivir Ab Nucleosides
US6403564B1 (en) * 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
RU2001113268A (en) * 1998-10-16 2003-09-27 Шеринг Корпорейшн (US) Combined therapy with ribavirin and interferon α to remove hepatitis C virus detected RNA in patients with chronic hepatitis C
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
AU2001255495A1 (en) 2000-04-20 2001-11-07 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rnain patients having chronic hepatitis c infection
US6673775B2 (en) 2001-04-18 2004-01-06 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection

Also Published As

Publication number Publication date
AR031572A1 (en) 2003-09-24
US6924270B2 (en) 2005-08-02
US20020055473A1 (en) 2002-05-09
US7115578B2 (en) 2006-10-03
EP1282632A1 (en) 2003-02-12
US20050004053A1 (en) 2005-01-06
WO2001081359A1 (en) 2001-11-01

Similar Documents

Publication Publication Date Title
AU2001255495A1 (en) Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rnain patients having chronic hepatitis c infection
AU1197600A (en) Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rnain patients having chronic hepatitis c infection
ZA988466B (en) Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
HK1016505A1 (en) Combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
DE60212048D1 (en) Catheter with improved distal pushing ability
AU4806600A (en) Medical suction valve
IL196301A0 (en) Medicament for the treatment of hapatitis c
AU2002321888A1 (en) Medical needle
AU2001265173A1 (en) Flexible endodontic syringe
AU2001234425A1 (en) Multi-lumen medical device
AU2002220268A1 (en) Anti-drawback medical valve
AU2001241963A1 (en) Improved medical procedure
AUPQ893200A0 (en) Medical residue treatment
AU2002254724A1 (en) Dual-profile steerable catheter
AU2002222853A1 (en) Therapeutic compounds
AU2002230684A1 (en) Dual element sensor medical electrode
AU2002303502A1 (en) Improved leads for the treatment of patients with chf
AU2002355230A1 (en) Blood dialyzer
HUP0200447A2 (en) Ribavirin-interferon alfa combination theory for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
AU2001243299A1 (en) Luminescent medical bandage
AU2001243515A1 (en) Combination drug therapy
AU2002322082A1 (en) Pharmaceutical composition for the treatment of viral infection
MXPA03006412A (en) Methods of administering epothilone analogs for the treatment of cancer.
AU2001232053A1 (en) System for the extracorporeal treatment of blood
AU2002213420A1 (en) Single-use syringe